Invizyne Technologies (IZTC) Competitors $12.00 +0.04 (+0.33%) As of 09/8/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. KRRO, TNXP, SGMT, ENGN, SOPH, ANNX, HUMA, ACIU, TKNO, and MNPRShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Korro Bio (KRRO), Tonix Pharmaceuticals (TNXP), Sagimet Biosciences (SGMT), enGene (ENGN), SOPHiA GENETICS (SOPH), Annexon (ANNX), Humacyte (HUMA), AC Immune (ACIU), Alpha Teknova (TKNO), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Korro Bio Tonix Pharmaceuticals Sagimet Biosciences enGene SOPHiA GENETICS Annexon Humacyte AC Immune Alpha Teknova Monopar Therapeutics Korro Bio (NASDAQ:KRRO) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment. Which has preferable earnings and valuation, KRRO or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Korro Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$2.27M149.41-$83.58M-$9.75-3.70Invizyne TechnologiesN/AN/AN/AN/AN/A Do institutionals and insiders have more ownership in KRRO or IZTC? 13.2% of Korro Bio shares are owned by institutional investors. 4.6% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend KRRO or IZTC? Korro Bio presently has a consensus target price of $86.83, indicating a potential upside of 140.40%. Given Korro Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Korro Bio is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to KRRO or IZTC? In the previous week, Korro Bio had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Korro Bio and 1 mentions for Invizyne Technologies. Korro Bio's average media sentiment score of 1.44 beat Invizyne Technologies' score of 0.00 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KRRO or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -61.51% -42.87% Invizyne Technologies N/A N/A N/A SummaryKorro Bio beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.02M$288.05M$5.81B$10.03BDividend YieldN/AN/A6.67%4.54%P/E RatioN/AN/A75.7526.29Price / SalesN/A435.43449.5181.86Price / CashN/A22.4425.7029.20Price / BookN/A11.1911.506.43Net IncomeN/A-$115.81M$3.28B$270.56M7 Day Performance23.71%3.60%1.30%3.01%1 Month Performance21.96%10.32%11.25%9.74%1 Year PerformanceN/A-14.07%59.54%26.68% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$12.00+0.3%N/AN/A$75.02MN/A0.0029KRROKorro Bio2.108 of 5 stars$25.35+14.1%$86.83+242.6%-19.3%$237.99M$2.27M-2.6070Positive NewsHigh Trading VolumeTNXPTonix Pharmaceuticals3.033 of 5 stars$27.09-2.0%$70.00+158.4%+77.5%$237.94M$10.09M-0.6950SGMTSagimet Biosciences3.3628 of 5 stars$7.27-1.2%$25.67+253.1%+179.0%$235.93M$2M-3.968ENGNenGene2.7311 of 5 stars$4.58-4.7%$23.29+409.0%-17.9%$233.99MN/A-2.7831Upcoming EarningsAnalyst ForecastGap DownSOPHSOPHiA GENETICS1.824 of 5 stars$3.43+2.4%$8.00+133.2%-11.5%$231.80M$65.17M-7.80520News CoverageANNXAnnexon2.6237 of 5 stars$2.09+0.7%$12.50+499.5%-61.6%$229.12MN/A-1.6260Positive NewsHUMAHumacyte2.7842 of 5 stars$1.45-4.3%$9.75+574.7%-73.2%$228.85M$1.57M-3.21150Positive NewsACIUAC Immune2.2228 of 5 stars$2.27+2.7%$12.00+428.6%-26.4%$228.43M$28.92M-3.92140News CoveragePositive NewsAnalyst ForecastTKNOAlpha Teknova2.2188 of 5 stars$4.23flat$10.00+136.4%-5.2%$226.35M$37.74M-10.07240Positive NewsMNPRMonopar Therapeutics3.1135 of 5 stars$36.65+8.0%$69.57+89.8%+1,635.6%$226.13MN/A-11.0110Analyst Forecast Related Companies and Tools Related Companies Korro Bio Alternatives Tonix Pharmaceuticals Alternatives Sagimet Biosciences Alternatives enGene Alternatives SOPHiA GENETICS Alternatives Annexon Alternatives Humacyte Alternatives AC Immune Alternatives Alpha Teknova Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IZTC Stock Alerts